Tag Archive for: diabetes

ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access

/in

Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation Validates ViCentra’s strategy and team, […]

Read more

ViCentra Strengthens Leadership Team to Accelerate Growth

/in

Karen Baxter, former VP & GM at Dexcom with deep expertise in diabetes device commercialization across Europe, joins as SVP Sales, Europe Jay Little, leader from Medtronic Diabetes, appointed VP Strategy & Business Development Team expansion will drive growth strategy, market development, and partnerships for scalable expansion to accelerate Kaleido’s growth across European markets Utrecht, […]

Read more

Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025

/in

Randomised, double-blinded, controlled BIG D-FOOT study demonstrates that local antibiotic delivery using STIMULAN® significantly reduces post-surgical infective complications in patients with diabetic foot osteomyelitis (DFO) Biocomposites symposium will explore best practice treatment strategies for complex infections and share findings from the BIG D FOOT study Keele, UK, 9 September 2025 – Biocomposites, an international medical […]

Read more

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump

/in

Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT Life Sciences and Health Innovations, demonstrating strong confidence in ViCentra’s next phase of growth Fresh capital fuels scale-up, regulatory pathway, and commercialization of Kaleido 2, the world’s smallest, lightest, and […]

Read more

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

/in

Atrogi’s breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle loss ATR-258 is set to enter Phase 2 trials […]

Read more